Global burden, trends and inequalities for ischaemic heart disease attributable to high fasting plasma glucose, high low-density lipoprotein cholesterol and high systolic blood pressure, 1990-2021: An analysis of the Global Burden of Disease Study 2021.

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Jun-Qiao An, Yu-Zhi Jia, Xiao-Han Shi, Xue He, Jin-Xi Zhang, Yue-Han Ren, Qing-Yong He
{"title":"Global burden, trends and inequalities for ischaemic heart disease attributable to high fasting plasma glucose, high low-density lipoprotein cholesterol and high systolic blood pressure, 1990-2021: An analysis of the Global Burden of Disease Study 2021.","authors":"Jun-Qiao An, Yu-Zhi Jia, Xiao-Han Shi, Xue He, Jin-Xi Zhang, Yue-Han Ren, Qing-Yong He","doi":"10.1111/dom.16199","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The three key and direct risk factors for the significant health issue prevalent worldwide, ischaemic heart disease(IHD), are high fasting plasma glucose (HFPG), high low-density lipoprotein (HLDL) and high systolic blood pressure (HSBP) in metabolic syndrome (MetS). A comprehensive study is essential to present the most recent global epidemiological trends.</p><p><strong>Methods: </strong>IHD data attributable to HFPG, HLDL and HSBP (3H) were obtained from the Global Burden of Disease Study (GBD) 2021. The absolute burden was manifested in the number of death cases and disability-adjusted life years (DALY). The relative burden was quantified through the age-standardized mortality rate (ASMR) and the age-standardized DALY rate (ASDR). Estimated annual percentage change (EAPC) was used to measure trends.</p><p><strong>Results: </strong>HSBP caused the greatest IHD burden, followed by HLDL, which was much higher than HFPG. The IHD burden associated with HLDL and HSBP were more alike and notably different from HFPG. From 1990 to 2021, ASDR for HSBP and HLDL-related IHD generally declined, with the EAPC of -1.28 (95% CI: -1.34, -1.23) and -1.38 (95% CI: -1.44, -1.33). But the trend was less pronounced for HFPG-related IHD, with the EAPC of -0.90 (95% CI: -2.25, 0.46). The absolute burden was higher in men under 80 and peaked 5-10 years earlier than women. Compared to HSBP and HLDL, HFPG caused a significant increase in burden in low-middle and low socio-demographic index (SDI) regions. The high-middle SDI region, which originally had the highest burden, showed a clear downward trend after 2005 and was gradually overtaken by the low-middle region. Eastern Europe, Central Asia, North Africa and the Middle East had the highest burden among the regions with the same SDI level in Europe, Asia and Africa.</p><p><strong>Conclusion: </strong>The HFPG-related IHD burden should be managed differently from HSBP and HLDL. Particular attention should be paid to men, older age groups and regions with low-middle SDI.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.16199","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: The three key and direct risk factors for the significant health issue prevalent worldwide, ischaemic heart disease(IHD), are high fasting plasma glucose (HFPG), high low-density lipoprotein (HLDL) and high systolic blood pressure (HSBP) in metabolic syndrome (MetS). A comprehensive study is essential to present the most recent global epidemiological trends.

Methods: IHD data attributable to HFPG, HLDL and HSBP (3H) were obtained from the Global Burden of Disease Study (GBD) 2021. The absolute burden was manifested in the number of death cases and disability-adjusted life years (DALY). The relative burden was quantified through the age-standardized mortality rate (ASMR) and the age-standardized DALY rate (ASDR). Estimated annual percentage change (EAPC) was used to measure trends.

Results: HSBP caused the greatest IHD burden, followed by HLDL, which was much higher than HFPG. The IHD burden associated with HLDL and HSBP were more alike and notably different from HFPG. From 1990 to 2021, ASDR for HSBP and HLDL-related IHD generally declined, with the EAPC of -1.28 (95% CI: -1.34, -1.23) and -1.38 (95% CI: -1.44, -1.33). But the trend was less pronounced for HFPG-related IHD, with the EAPC of -0.90 (95% CI: -2.25, 0.46). The absolute burden was higher in men under 80 and peaked 5-10 years earlier than women. Compared to HSBP and HLDL, HFPG caused a significant increase in burden in low-middle and low socio-demographic index (SDI) regions. The high-middle SDI region, which originally had the highest burden, showed a clear downward trend after 2005 and was gradually overtaken by the low-middle region. Eastern Europe, Central Asia, North Africa and the Middle East had the highest burden among the regions with the same SDI level in Europe, Asia and Africa.

Conclusion: The HFPG-related IHD burden should be managed differently from HSBP and HLDL. Particular attention should be paid to men, older age groups and regions with low-middle SDI.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信